Old Web
English
Sign In
Acemap
>
authorDetail
>
Montse Cortés
Montse Cortés
Clinical trial
Diffuse large B-cell lymphoma
CHOP
Medicine
Pegfilgrastim
2
Papers
28
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
2013
Nuclear Medicine Communications
Eva González Barca
Miguel Canales
Montse Cortés
M. Jesus Vidal
Antonio Salar
Albert Oriol
Joan Bargay
José Luis Bello
José Javier Sánchez
José-Francisco Tomás
Eva Donato
Secundino Ferrer
Dolores Caballero
Show All
Source
Cite
Save
Citations (26)
Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain.
2010
Blood
Eva González-Barca
Miguel Canales
María Jesús Vidal
Albert Oriol
Antonio Salar
Joan Bargay
Montse Cortés
J. Coya
José Francisco Tomás
Andrés López
José Javier Sánchez
Eva Donato
Andrés Llorente
Secundino Ferrer
Dolores Caballero
Show All
Source
Cite
Save
Citations (2)
1